GlobalData on MSN3d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
A recombinant anti-CD38 fully human monoclonal antibody injection, HLX15 comes in both intravenous and subcutaneous ...
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...
Business Wire4d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma. The agreement combines Dr. Reddy’s global commercial ...
Daily3d
Dr Reddy's Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, Europe
Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...
The Week4d
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius Biotech, Inc to develop and commercialise an under-development cancer drug. Dr Reddy’s ...
Yahoo Finance3d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.
Pharmabiz4d
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...
money.rediff4d
Dr Reddy's Subsidiary Partners with Henlius for Cancer Drug
Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and ...
Dr. Reddy’s, Shanghai Henlius Biotech ink $131.6 million cancer drug deal
Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.